Neurology

Karuna Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
Monday, March 20, 2023
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Psychiatry, Attention, Telephone, Morgan Stanley, J.P. Morgan & Co., Sale, Karuna, Goldman Sachs, Prospectus, KRTX, Security (finance), Therapy, 2nd Floor, Broadridge Financial Solutions

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it has commenced an underwritten public offering of $400.0 million of its common stock.

Key Points: 
  • Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it has commenced an underwritten public offering of $400.0 million of its common stock.
  • Karuna also intends to grant the underwriters a 30-day option to purchase an additional $60.0 million of its common stock.
  • All the shares in the proposed offering are to be sold by Karuna.
  • Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC are acting as joint book-running managers for the offering.

Altoida Announces Upcoming Poster Presentations at AD/PD 2023

Retrieved on: 
Monday, March 20, 2023
Technology, Mental Health, Medical Devices, Neurology, Health Technology, Biotechnology, Health, General Health, Artificial Intelligence, Augmented reality, Alzheimer's disease, DSM-IV codes, AI, International Conference on Emerging Infectious Diseases, Conference, AR

Altoida, Inc ., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced two poster presentations at the upcoming AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, on March 28–April 1, 2023 in Gothenburg, Sweden.

Key Points: 
  • Altoida, Inc ., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced two poster presentations at the upcoming AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, on March 28–April 1, 2023 in Gothenburg, Sweden.
  • Details of the presentations are as follows:
    Presenter: Florencia Iulita, Ph.D., Head of Medical Strategy and Operations, Altoida

IMAC Holdings and Brain Scientific Announce a Strategic Merger to Create Synergistic End-To-End Neurological Solution

Retrieved on: 
Monday, March 20, 2023
CE, Letter, Stroke, DSM-IV codes, Rehabilitation, Neurology, Certification, Alzheimer's disease, Science, Patient, EEG, Hypokinesia, Diagnosis, Growth, Neuro, FDA, IMAC, BACK, Medical imaging, Medical device

BRENTWOOD, Tenn. and LAKEWOOD RANCH, Fla., March 20, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (“IMAC”)(Nasdaq: BACK), a regenerative rehabilitation company focused on treating musculoskeletal and neurodegenerative disease, and Brain Scientific, Inc. (“Brain Scientific”)(OTCQB:BRSFD), a Florida-based applied science technology company, jointly announced today that they have executed a binding Letter of Intent to combine companies in a strategic merger-of-equals (the “Transaction”).

Key Points: 
  • Together, the companies would provide patients with true end-to-end neurological solutions using Brain Scientific’s diagnostic and motion technologies and IMAC’s regenerative rehabilitation medical services.
  • Hassan Kotob, Chief Executive Officer of Brain Scientific, is expected to serve as Chairman and CEO of the combined company.
  • Brain Scientific’s disposable NeuroCap and portable NeuroEEG enable neurologists to save time, see more patients, and eliminate contamination risks.
  • Olshan Frome Wolosky LLP is serving as legal counsel for IMAC, and Lucosky Brookman LLP is serving as legal counsel for Brain Scientific.

Therapeutic Solutions International Spin Off Campbell Neurosciences Creates Saliva Based Test for Suicidal Ideations

Retrieved on: 
Monday, March 20, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Suicidal ideation, Suicide, Group 1, Group 3, Homicide, TSOI, ClinicalTrials.gov, Campbell, CDC, Group 2, Death, Patient, Risk, Use-centered design, Saliva, Pharmaceutical industry

Therapeutic Solutions International (TSOI) announced today its Spin Off Company, Campbell Neurosciences, Inc., obtained successful validation of its suicidal ideation predictive test using a saliva based system.

Key Points: 
  • Therapeutic Solutions International (TSOI) announced today its Spin Off Company, Campbell Neurosciences, Inc., obtained successful validation of its suicidal ideation predictive test using a saliva based system.
  • Previously the Company reported successful stratification of suicidal tendencies using a proprietary blood-based biomarker.
  • Additionally, suicide is the second leading cause of death among individuals between the ages of 10-34.
  • “The prospects of a simple saliva-based test will allow for a more personalized approach to regenerative psychiatry, which in the end will result in more lives saved,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International.

FORE Biotherapeutics Receives FDA Orphan Drug Designation for FORE8394 for the Treatment of Primary Brain and CNS Malignancies

Retrieved on: 
Monday, March 20, 2023
Neurology, Biotechnology, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Other Health, China Biologic Products, Central nervous system, Drug development, ODD, Neoplasm, ESMO, Cancer, BRAF, Genomics, CNS, Trial of the century, V600, Malignancy, Patient, FORTE, Fore, Rare, European Society for Medical Oncology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Food, RAF, Pharmaceutical industry

FORE Biotherapeutics (FORE Bio) a precision stage oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead program, FORE8394, for the treatment of primary brain and central nervous system (CNS) malignancies.

Key Points: 
  • FORE Biotherapeutics (FORE Bio) a precision stage oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead program, FORE8394, for the treatment of primary brain and central nervous system (CNS) malignancies.
  • This is the first orphan drug designation received by FORE Bio and the FORE8394 program.
  • "The receipt of Orphan Drug Designation is another important regulatory achievement that reinforces the FDA's recognition of the potential of FORE8394 to improve clinical outcomes in patients with BRAF-altered brain tumors,” said Stacie Shepherd, M.D., Ph.D., Chief Medical Officer of Fore Biotherapeutics.
  • Orphan Drug Designation is granted to drugs or biological products for the treatment of rare diseases or conditions that impact fewer than 200,000 people in the United States.

Synchron to Begin Patient Enrollment for the COMMAND Trial of Brain-Computer Interface at Gates Vascular Institute

Retrieved on: 
Monday, March 20, 2023
Hardware, FDA, Health Technology, Technology, Nanotechnology, Surgery, Medical Devices, Neurology, Clinical Trials, Biotechnology, Science, Software, Other Science, Research, Health, Mobile, Wireless, Extremities, UB, Kaleida Health, University, Gates Vascular Institute, BCI, Jacobs School of Medicine and Biomedical Sciences, COMMAND, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, MBA, Brain, Biomedical sciences, CMO, Doctor of Philosophy, Computer, Jacobs Institute for Design Innovation, Trial of the century, Paralysis, Blood, Motor cortex, University of Pittsburgh Medical Center, Professor, MD, FAHA, Patient, Physician, SUNY, FACS, SUNY UB, EFS, IDE, Mount Sinai Health System, JAMA Neurology, Safety, Medical imaging, Medical device, Management, Medicine, Beckman Coulter, Neurosurgery

The COMMAND trial is being conducted under the first investigational device exemption (IDE) awarded by the FDA to a company assessing a permanently implanted BCI.

Key Points: 
  • The COMMAND trial is being conducted under the first investigational device exemption (IDE) awarded by the FDA to a company assessing a permanently implanted BCI.
  • The new site at Gates Vascular Institute marks the third approved COMMAND trial location, joining Mount Sinai Health System in New York and the University of Pittsburgh Medical Center.
  • The FDA granted Breakthrough Device designation to Synchron in August 2020 and an IDE in July 2021.
  • There is no guarantee of participation and principal investigators make the final determination of patient eligibility.

Anthem Blue Cross Helps Health Centers in Underserved Regions of California Offer Specialty Healthcare Services to Uninsured Patients

Retrieved on: 
Monday, March 20, 2023
Women, Technology, Managed Care, General Health, Men, Family, Apps, Applications, Consumer, Optical, Teens, Neurology, Mental Health, Children, Hospitals, Health Insurance, Philanthropy, Software, Health, Fund Raising, Internet, Dorado, Insurance, Mono, Travel, Health equity, Coalition, Elevance Health, Organization, Federally Qualified Health Center, Patient, Blue Cross, Hospital, Nursing

Anthem Blue Cross, a leading coordinator of managed healthcare services in California, has made a new commitment that will continue to give uninsured Californians access to specialty healthcare services.

Key Points: 
  • Anthem Blue Cross, a leading coordinator of managed healthcare services in California, has made a new commitment that will continue to give uninsured Californians access to specialty healthcare services.
  • Anthem has provided a new grant of $50,000 to California E-Consult Coalitions that will be distributed to Federally Qualified Health Centers (FQHCs), rural health centers and tribal FQHCs in California's Central Valley, north rural and Sacramento regions, so the health centers can continue accessing e-consults with specialty providers to treat patients, regardless of whether patients have health insurance.
  • Along with a previous grant, Anthem has invested $100,000 since 2020 to cover the cost of more than 1,000 e-consults for uninsured patients.
  • “Anthem Blue Cross is committed to fortifying our members as well as our communities with equal opportunities to access the healthcare they need and to improve their health outcomes,” said Les Ybarra, President of Anthem Blue Cross’s Medi-Cal health plan.

IMAC Holdings and Brain Scientific Announce a Strategic Merger to Create Synergistic End-To-End Neurological Solution

Retrieved on: 
Monday, March 20, 2023
CE, Letter, DSM-IV codes, Rehabilitation, Neurology, Certification, Science, Patient, EEG, Hypokinesia, Diagnosis, Growth, Neuro, FDA, IMAC, BACK, Medical imaging, Medical device

Together, the companies would provide patients with true end-to-end neurological solutions using Brain Scientific’s diagnostic and motion technologies and IMAC’s regenerative rehabilitation medical services.

Key Points: 
  • Together, the companies would provide patients with true end-to-end neurological solutions using Brain Scientific’s diagnostic and motion technologies and IMAC’s regenerative rehabilitation medical services.
  • Hassan Kotob, Chief Executive Officer of Brain Scientific, is expected to serve as Chairman and CEO of the combined company.
  • Brain Scientific’s disposable NeuroCap and portable NeuroEEG enable neurologists to save time, see more patients, and eliminate contamination risks.
  • “We believe that a Brain Scientific and IMAC merger would allow us to accelerate our growth and expand into new channels and markets to provide those suffering from neurological disorders with the best care possible.”

CO2 Medical Laser Systems Global Market Report 2023: Growing Demand for Cosmetic Dentistry and Aesthetic Procedures Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, March 20, 2023
Health, Dental, Medical Devices, Dentistry, Infection, Blepharoplasty, United States National Library of Medicine, Stent, Gynaecology, US Foods, Obesity, National Centre for Infectious Diseases, Bleeding, IgG4-related ophthalmic disease, Prevalence, Diabetes, Dermatitis, Food, NCBI, Cardiovascular disease, Skin, Woman, National Center for Biotechnology Information, CVD, Polycystic ovary syndrome, USD, Heart, American Society of Plastic Surgeons, National library, Dermatology, Laser, Urology, Developed country, Application, PCOS, Ophthalmology, Oral hygiene, Conditional sentence, Growth, Region, Plastic, FDA, Neurology, CO2, World Health Organization, Medical device, Health care, Veterinary medicine, Pharmaceutical industry

The "CO2 Medical Laser Systems Market by Type, by Application, by End User, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CO2 Medical Laser Systems Market by Type, by Application, by End User, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.
  • Increasing healthcare spending, growing demand for cosmetic dentistry and improved aesthetic appearance, and adoption of technological advancements are other factors supporting the market growth.
  • The number of CVD-related preventive and therapeutic procedures has increased recently, which has boosted demand for CO2 laser cutting equipment.
  • In 2022, North America region accounted for the highest revenue in the CO2 medical laser market during the forecast period.

Cure Rare Disease Welcomes Leading Experts to Scientific Advisory Board

Retrieved on: 
Monday, March 20, 2023
Infectious Diseases, Neurology, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, SAB, Tic disorder, Duchenne muscular dystrophy, MBA, CRD, Duchenne, NIH Intramural Research Program, Harvard Medical School, Biochemistry, Molecular genetics, SCA3, Cardiology, ASO, Rare, ADSSL1, Vaccine, Management, Pediatrics

As part of their role, SAB members help advance CRD's preclinical and clinical development of its gene therapy and antisense oligonucleotide (ASO) programs, providing strategic advice on scientific, regulatory, and clinical matters.

Key Points: 
  • As part of their role, SAB members help advance CRD's preclinical and clinical development of its gene therapy and antisense oligonucleotide (ASO) programs, providing strategic advice on scientific, regulatory, and clinical matters.
  • The members of the newly appointed SAB bring a wealth of expertise and experience in the areas of treatment and therapeutic development for neuromuscular diseases.
  • "Their insights and guidance will be critical as we continue to advance our programs and work towards our goal of providing life-saving treatments to individuals with rare diseases."
  • Collectively, these programs offer pragmatic hope of treatment to more than 200,000 Americans living with rare and ultra-rare diseases.